Clinical tests of therapeutical failures based on mathematical modeling of the HIV infection

IEEE Transactions on Automatic Control

Volumn 53, Issue SPECIAL ISSUE, 2008, Pages 230-241

  Ouattara, Djomangan Adama ^a,b   Mhawej, Marie José ^b   Moog, Claude H ^b  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ECOLE CENTRALE DE NANTES   (France)

Author keywords

AIDS; Clinical trial; Discretization; Early diagnosis; HIV; Identifiability; Nonlinear systems; Parameter estimation; Therapeutical failures

Indexed keywords

AIDS CLINICAL TRIAL; DISCRETIZATIONS; EARLY DIAGNOSIS; HIV; IDENTIFIABILITY; CLINICAL TEST; MATHEMATICAL CHARACTERIZATION; THERAPEUTICAL FAILURES;

COMPUTER SIMULATION; EXPERIMENTS; NONLINEAR SYSTEMS; CONTINUOUS TIME SYSTEMS; DIAGNOSIS; DISCRETE TIME CONTROL SYSTEMS; IMMUNOLOGY; INVARIANCE; MATHEMATICAL MODELS; VIRUSES;

PARAMETER ESTIMATION;

EID: 39849092256     PISSN: 00189286     EISSN: None     Source Type: Journal    
DOI: 10.1109/TAC.2007.911332     Document Type: Article

References (37)

1. A. S. Perelson and P. W. Nelson, "Mathematical analysis of HIV-1 dynamics in vivo," SIAM Rev., vol. 41, no. 1, pp. 3-44, 1999.
2. A. S. Perelson, P. Essunger, Y Cao, M. Vesanen, A. Hurley, K. Saksela, M. Markowitz, and D. D. Ho, "Decay characteristics of HIV-1 infected compartment during combination therapy," Nature, vol.387, pp. 188-191, 1997.
3. D. D. Ho et al., "Rapid turnover of plasma virion and CD4 lymphocytes in HIV-1 infection," Nature, vol.373, pp. 123-126, Jan. 1995.
4. X. Wei et al., "Viral dynamics in human immunodeficiency virus type 1 infection," Nature, vol.373, pp. 117-122, Jan. 1995.
5. R. Arnaout, M. Nowak, and D. Wodarz, "HIV-1 dynamics revisited: Biphasic decay by cytotoxic T lymphocyte killing," Proc. Royal Society, vol.267, pp. 1347-1354, 2000.
6. R. A. Filter, X. Xia, and C. M. Gray, "Dynamic HIV/AIDS parameter estimation with application to a vaccine readiness study in Southern Africa," IEEE Trans. Biomed. Eng., vol. 52, no. 5, pp. 284-291, May 2005.
7. X. Xia and C. H. Moog, "Identifiability of nonlinear systems with application to HIV/AIDS models," IEEE Trans. Autom. Control, vol. 48, no. 2, pp. 330-336, Feb. 2003.
8. M. A. Nowak and R. M. May, Virus Dynamics: Mathematical Principles of Immunology and Virology. Oxford, U.K.: Oxford Univ. Press, 2002.
9. D. Kirschner and G. F. Webb, "Understanding drug resistance for monotherapy treatment of HIV infection," Bull. Math. Biol., vol. 59, no. 4, pp. 763-785, 1997.
10. D. A. Ouattara, "Mathematical analysis of the HIV-1 infection: Parameter estimation, therapies effectiveness, and therapeutical failures," in Proc. 27th Annu. Int. Conf. IEEE Eng. Med. Biol. Soc., Shanghai, China, Sep. 2005, pp. 821-824.
11. A. M. Jeffrey, X. Xia, and I. K. Craig, "When to initiate HIV therapy: A control theoretic approach," IEEE Trans. Biomed. Eng., vol. 50, no. 11, pp. 1213-1220, Nov. 2003.
12. I. Craig and X. Xia, "Can HIV/AIDS be controlled?," IEEE Control Syst. Mag., vol. 25, no. 1, pp. 80-83, Feb. 2005.
13. H. Shim, S. J. Han, H. Shim, S. W. Nam, and J. H. Seo, "Optimal scheduling of drug treatment for HIV infection: Continuous dose control and receding horizon control," Int. J. Control, Automat., Syst., vol. 1, no. 3, pp. 282-288, Sep. 2003.
14. R. Zurakowski and R. A. Teel, "A model predictive control based scheduling method for HIV therapy," J. Theoret. Biol., pp. 368-382, Jul. 2006.
15. D. Wodarz et al., "A new therory of cytotoxic T-lymphocyte memory: Implication for the HIV treatement," Phil. Trans. R. Soc. Lond., vol.355, pp. 329-343, 2000.
16. D. A. Ouattara and C. H. Moog, "Modelling of the HIV/AIDS infection: An aid for an early diagnosis of patients," in Biology and Control Theory: Current Challenges. Berlin, Germany: Springer-Verlag, 2007, Springer Series in Lecture Notes in Control and Information Sciences (LNCIS).
17. S. Ammar and J. C. Vivalda, "On the preservation of observability under sampling," Syst. Control Lett., vol.52, pp. 7-15, 2004.
18. S. Ammar, "Observability and observateur under sampling," Int. J. Control, vol. 79, no. 9, pp. 1039-1045, Sep. 2006.
19. S. Nõmm, "Realization and identifiability of discrete-time nonlinear systems," Ph.D. dissertation, Inst. Comm. Cybern. Nantes (IRCCyN), Tallinn Univ. of Technol. and Ecole Centrale de Nantes, Nantes, France, 2004.
20. D. A. Ouattara, "Modélisation de L'infection par le VIH, Identification et Aide au Diagnostic," Ph.D. dissertation, Inst. Comm. Cybern. Nantes (IRCCyN), Ecole Centrale de Nantes and Univ. de Nantes, Nantes, France, 2006.
21. R. A. Filter and X. Xia, "A penalty function to HIV/AIDS model parameter estimation," in Proc. 13th IFAC Symp. Syst. Identification, Rotterdam, The Netherlands, 2003, pp. 27-29.
22. D. A. Ouattara, M.-J. Mhawej, and C. H. Moog, Software for the Estimation of the Parameters of the HIV/AIDS Infection [Online]. Available: http://www.vih.irccyn.ec-nantes.fr
23. J. Kim, W. H. Kim, H. Shim, and C. C. Chung, "Constant drug dose leading long-term non-progressor for HIV-infected patients with RTI and PI," in Proc. 44th IEEE Conf. Decision Control/Eur. Control Conf., Seville, Spain, Dec. 2005, pp. 909-918.
24. D. Wodarz and M. A. Nowak, "CD8 memory, immuonodominance, and antigenic escape," Eur. J. Immunol., vol.30, pp. 2704-2712, 2000.
25. J.-F. Delfraissy, Prise en Charge Thérapeutique des Personnes Infectées par le VIH : Recommandations du Groupe D'experts Médecine-Sciences, Paris, 2004 [Online]. Available: http://www. ladocumentationfrancaise.fr/brp/notices/044000467.shtml,flammarion
26. I. T. Prud'homme et al., "Amplicor HIV Monitor, NASBA HIV-1 RNA QTand Quantiplex HIVRNAversion 2.0 viral load assays: A Canadian evaluation, " J. Clin. Virol., vol.11, pp. 189-202, 1998.
27. A. Berger et al., "Comparative evaluation of the COBAS Amplicor HIV-1 Monitor™ ultrasensitive test, the new COBAS AmpliPrep/ COBAS Amplicor HIV-1 Monitor™ and the versant HIV RNA 3.0 assays for quantitation of HIV-1 RNA in plasma samples," J. Clin. Virol., vol.33, pp. 43-51, 2005.
28. R. Galli, L. Merrick, M. Friesenhahn, and R. Ziermann, "Comprehensive comparison of the Versant® HIV-1 RNA 3.0 (bDNA) and COBAS Amplicor HIV-1 Monitor® 1.5 assays on 1000 clinical specimens," J. Clin. Virol., vol.34, pp. 245-252, 2005.
29. K. Israel-Ballard et al., "Taqman rt-pcr and Versant® HIV-1 RNA 3.0 (bDNA) assay quantification of HIV-1 RNA viral load in breast milk," J. Clin. Virol., vol.34, pp. 253-256, 2005.
30. Fiches Techniques de la Firme Roche 2003 [ Online]. Available: http:// www.roche-diagnostics.fr
31. Guidelines for the use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents U.S. Dept. Health and Human Services 2006 [Online]. Available: http://www.aidsinfo.nih.gov/guidelines
32. A. S. Perelson, A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho, "HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time," Science, vol.271, pp. 1582-1586, 1996.
33. D. Kirschner, S. Lenhart, and S. Serbin, "Optimal control of the chemotherapy of HIV," J. Math. Biol, vol.35, pp. 775-792, 1997.
34. J. Alvarez-Ramirez et al., "Feedback control of the chemotherapy of HIV," Int. J. Bifurc. Chaos, vol. 10, no. 9, pp. 2207-2219, 2000.
35. F. Biafore and C. E. D'Attellis, "Exact linearisation and control of an HIV-1 predator-prey model," in Proc. 27th Annu. Int. Conf. IEEE Eng. Med. Biol. Soc., Shanghai, China, Sep. 2005, pp. 2367-2370.
36. A. M. Jeffrey, "A control theoretic approach to HIV/AIDS drug dosage desing and timing the initiation of therapy," Ph.D. dissertation, Dept. Elect. Electron., Comput., Eng., Univ. of Pretoria, Pretoria, South Africa, 2006.
37. D. A. Ouattara and C. H. Moog, "Identification, linéarisation et commande optimale du modèle 3-D de l'infection VIH-1," in Proc. CIFA, Bordeaux, France, May 2006, p. 152.